Browse HPGD

Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF00106 short chain dehydrogenase
Function

Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells.

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007292 female gamete generation
GO:0007565 female pregnancy
GO:0007567 parturition
GO:0019372 lipoxygenase pathway
GO:0030728 ovulation
GO:0033559 unsaturated fatty acid metabolic process
GO:0044706 multi-multicellular organism process
GO:0045786 negative regulation of cell cycle
GO:0048514 blood vessel morphogenesis
GO:0048844 artery morphogenesis
GO:0060840 artery development
GO:0070493 thrombin receptor signaling pathway
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0097070 ductus arteriosus closure
GO:1901568 fatty acid derivative metabolic process
GO:2001300 lipoxin metabolic process
Molecular Function GO:0004953 icosanoid receptor activity
GO:0004954 prostanoid receptor activity
GO:0004955 prostaglandin receptor activity
GO:0004957 prostaglandin E receptor activity
GO:0016404 15-hydroxyprostaglandin dehydrogenase (NAD+) activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0048037 cofactor binding
GO:0050662 coenzyme binding
GO:0051287 NAD binding
GO:0070403 NAD+ binding
Cellular Component GO:0016323 basolateral plasma membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2142753: Arachidonic acid metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-2142700: Synthesis of Lipoxins (LX)
R-HSA-2162123: Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HPGD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HPGD and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19494278Colon Carcinoma; Prostate CarcinomaPromote immunityPGDH-mediated antitumor effect was associated with attenuated tumor-induced immune suppression and substantially reduced secretion of immunosuppressive mediators and cytokines such as PGE(2), IL-10, IL-13, and IL-6 by intratumoral CD11b cells. We show also that introduction of 15-PGDH gene in tumor tissue is sufficient to redirect the differentiation of intratumoral CD11b cells from immunosuppressive M2-oriented F4/80(+) tumor-associated macrophages (TAM) into M1-oriented CD11c(+) MHC class II-positive myeloid APCs.
19887544Breast Carcinoma; Colon CarcinomaPromote immunityPreclinical and clinical evidence shows that cyclooxygenase-2 (Cox-2)-mediated prostaglandin E(2) (PGE(2)) overexpression plays an important role in tumor growth, metastasis, and immunosuppression. It has been shown that expression of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a key enzyme responsible for PGE(2) inactivation, is suppressed in the majority of cancers, including breast and colon carcinoma. The in vitro study showed that Ad-mediated 15-PGDH expression significantly decreased proliferation and migration of cancer cells. Animal breast and colon tumor therapy studies showed that 15-PGDH gene therapy produced a significant delay in 2LMP and LS174T tumor growth. Combined therapy using 15-PGDH and anti-VEGF antibody (bevacizumab) significantly increased inhibition of growth of LS174T tumor xenografts in comparison with agents alone.
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HPGD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HPGD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9340.29
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1120.581
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8240.554
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8580.327
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5260.775
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.260.498
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9810.171
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6340.275
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0250.99
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2490.31
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.9390.0547
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2510.498
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HPGD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HPGD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HPGD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HPGD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HPGD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HPGD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HPGD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHPGD
Namehydroxyprostaglandin dehydrogenase 15-(NAD)
Aliases SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ......
Chromosomal Location4q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HPGD collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HPGD.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144